David Bermudes

Papers

Total Citations

792

H-Index

About

David Bermudes is a pioneering researcher in the field of bacterial cancer therapy, best known for engineering tumour-targeting bacteria to fight cancer. His landmark 2018 paper, "Tumour-targeting bacteria engineered to fight cancer," has garnered over 790 citations, cementing his influence in the development of live biotherapeutic agents for oncology. Bermudes' major contributions lie in designing genetically modified bacteria—particularly Salmonella strains—that selectively colonize and destroy solid tumours while sparing healthy tissue. His work bridges microbiology, synthetic biology, and immunotherapy, offering a novel approach to overcoming drug resistance and tumour hypoxia. Beyond this flagship study, Bermudes has advanced the understanding of bacterial motility, virulence attenuation, and therapeutic payload delivery, with his research frequently cited in reviews on microbial cancer therapy. His achievements include patents for bacterial-based cancer treatments and collaborations that have moved these concepts toward clinical translation. For students and researchers, Bermudes exemplifies how interdisciplinary thinking can transform a classic pathogen into a precision weapon against cancer, opening new avenues for targeted, living medicines.